ライフサイエンスコーパス: viruria

1 re associated with a higher frequency of BKV viruria.

2 he adult kidney, where reactivation leads to viruria.

3 BK viremia and after no intervention for JC viruria.

4 following transplantation did not prevent BK viruria.

5 JCV seronegative patients, 10 (37%) had JCV viruria.

6 les from renal allograft recipients with BKV viruria.

7 ositive cytology compared with those without viruria.

8 g BK viremia (0.161 vs. 0.065, P=0.0378) and viruria (0.303 vs. 0.146, P=0.0067) compared with Group

9 both viremia (0.297 vs. 0.261, P=0.6061) and viruria (0.437 vs. 0.389, P=0.5363).

10 equent in putative rejection with concurrent viruria (48.6%), compared with rejection before (9.1%) o

11 Ninety-five (40%) patients had sustained viruria, 48 (20%) sustained viremia, and 17 (7%) biopsy-

12 V viruria was far more common (37%) than BKV viruria (5%) in HIV-seronegative persons.

13 iruric donors were more likely to develop BK viruria (66.6% vs 7.8%; P < .001) and viremia (66.6% vs

14 Of 666 recipients, 250 (37.5%) developed viruria, 80 (12%) developed viremia and 31 (4.7%) develo

15 ing of urinary Haufen and not BK viremia and viruria accurately mark BK polyomavirus nephropathy.

16 ed nephropathy (BKVAN), viremia/DNAemia, and viruria after renal transplantation.

17 omavirus BK (BKV) infection characterized by viruria alone is considered to be of little clinical sig

18 Among these, 33 had BK viruria alone, 61 had BK viremia with viruria and 25 had

19 itis is far less frequent than BK viremia or viruria, analysis of risk factors for BKV nephritis as a

20 had BK viruria alone, 61 had BK viremia with viruria and 25 had significant viremia defined as BKV DN

21 Viruria and DNAemia patterns were investigated in 205 se

22 a significant risk factor for posttransplant viruria and viremia (OR, 4.52; CI, 2.33-8.77; P < 0.0001

23 ents with BKV nephropathy than in those with viruria and viremia (P = 0.045).

24 dergoing allogeneic HCT, we quantified BKPyV viruria and viremia (pre-HCT and at Months 1-4, 8, 12, a

25 dergoing allogeneic HCT, we quantified BKPyV viruria and viremia (pre-HCT and at months 1-4, 8, 12, a

26 or the occurrence of BKV infections using BK viruria and viremia as endpoints.

27 comparing the results of JCV serology to JCV viruria and viremia in 67 patients enrolled in a single-

28 Donor BK viruria is associated with early BK viruria and viremia in kidney transplant recipients.

29 BK viruria and viremia resolved after cessation of IS and n

30 Intermittent viruria and viremia was observed throughout the study.

31 statistics showed fair to good agreement of viruria and viremia with BK polyomavirus nephropathy or

32 may act as the source of virus resulting in viruria and viremia.

33 BKV positive earlier than in the group with viruria and viremia.

34 One patient with asymptomatic viruria and with a viral load overlapping values seen in

35 l reactivation occurs first in the urine (BK viruria) and is associated with a high risk of transplan

36 At baseline, 39% of patients had viruria, and 24% had DNAemia.

37 ia, slightly rose to 4.35 ng/mmol with BKPyV viruria, and then markedly increased to 16.42 ng/mmol wh

38 ive and specific, but periods of viremia and viruria are brief, limiting the utility of ZIKV RNA assa

39 In young seropositive women, CMV DNAemia and viruria are common, which suggests that naturally acquir

40 e planned follow-up period or development of viruria because the trial was stopped early owing to lac

41 hain reaction or in longitudinal DNAemia and viruria between the women with and without serological e

42 fter platelet engraftment with documented BK viruria [BK-HC]) were compared with matched controls.

43 e recipient older age, male sex, donor BKPyV-viruria, BKPyV-seropositive donor/-seronegative recipien

44 nflammation and tubulitis in the presence of viruria but negative for BKV stains were designated as p

45 igher in renal allograft recipients with BKV viruria, but 58 (50.4%) of 115 renal biopsy samples test

46 Twenty-four women (9.2%) had detectable CMV viruria by qualitative PCR.

47 Viruria clearance was infrequent (15.6%).

48 sing decoy cells as a marker of polyomavirus viruria cytology has a sensitivity of 41.9% and negative

49 thology in concomitant renal biopsies and BK viruria (decoy cell shedding and viral load assessments

50 primary outcome was time to occurrence of BK viruria (detected using quantitative real-time polymeras

51 ains derived from patients with asymptomatic viruria did not show complete separation from strains as

52 are already significantly elevated in BKPyV viruria (especially with decoy cell shedding) and furthe

53 Furthermore, ZIKV viruria from infected AG6 mice can causes mosquito infec

54 We studied 230 patients with sustained viruria from whom multiple samples taken after a median

55 a greater than 5 x 103 copies/ml and with BK viruria greater than 107 copies/ml in all cases.

56 % had viremia >=10 000 copies/mL and 45% had viruria >=109 copies/mL in the first 3 months post-HCT.

57 had viremia >=10 000 copies/mL, and 45% had viruria >=109 copies/mL in the first three months post-H

58 ted associations of peak viremia >=10 000 or viruria >=109 copies/mL with estimated kidney function (

59 ted associations of peak viremia >=10 000 or viruria >=109 copies/mL with estimated kidney function (

60 Women with CMV viruria had significantly higher rates of HIV perinatal

61 also decreased the rates of CMV viremia and viruria, herpes simplex virus disease, and the use of in

62 settings: (i) patients with asymptomatic BK viruria, (ii) patients with active BKVAN, and (iii) pati

63 olymerase chain reaction (PCR) for detecting viruria in 100 urine samples.

64 assess their impact on JC and BK viremia and viruria in 15 healthy subjects, eight human immunodefici

65 ) viruria is more common than BK virus (BKV) viruria in healthy individuals but in kidney transplants

66 Clinical studies have shown that Zika viruria in patients persists for an extended period, and

67 -five recipients (40%) had posttransplant BK viruria including 61 with additional viremia and 22 with

68 Donor BK viruria is associated with early BK viruria and viremia

69 at intrarenal viral replication in sustained viruria is frequently associated with putative acute rej

70 immunosuppressed patients with polyomavirus viruria is largely supportive and directed toward minimi

71 JC virus (JCV) viruria is more common than BK virus (BKV) viruria in he

72 he presence of BK viruria made concurrent JC viruria less likely: JC viruria was detected in 22% of n

73 In comparison, BK viremia and viruria levels by PCR showed only modest correlations wi

74 athy led to resolution of viremia, decreased viruria levels, and disappearance of viral inclusions, b

75 The presence of BK viruria made concurrent JC viruria less likely: JC virur

76 Compared with no viruria (n=515), sustained viruria was associated with m

77 pecificity and positive predictive value for viruria (not viral nephropathy) are 100%.

78 BK viruria occurred in 22 patients (29%) in the levofloxaci

79 polyomavirus reactivation (BK viremia or JC viruria) on antibodies to kidney-specific self-antigens

80 94 developed BKV infection (any degree of BK viruria or viremia) whereas 146 developed no infection.

81 cipient JC seropositivity did not predict BK viruria or viremia.

82 significantly higher incidence rates of BKV viruria, Pneumocystis jiroveci pneumonia, and malignancy

83 tive polymerase chain reaction [PCR]) and BK viruria (quantitative PCR and decoy cell counts).

84 BK viruria resolved within 4 to 12 weeks (after 1-4 doses)

85 reased; however, after cessation of therapy, viruria returned to near pretreatment levels.

86 s were 2.31 ng/mmol in samples without BKPyV viruria, slightly rose to 4.35 ng/mmol with BKPyV viruri

87 lant recipients define levels of viremia and viruria that are actionable for additional testing or in

88 A BKV viruria threshold of >2.5E+07 copies/mL had 100% sensiti

89 The incidence of BK viruria, viremia and nephropathy was not significantly d

90 -occurrence was 7.6, 7.9, and 9.7 months for viruria, viremia, and polyomavirus-associated nephropath

91 In this cross-sectional study, BKV viruria, viremia, and urinary decoy cells were detected

92 following kidney transplantation, leading to viruria, viremia, and, ultimately, PVAN, is associated w

93 The overall incidence of JC viruria was 43 of 105 (40.9%) subjects, with a marked in

94 The onset of JC viruria was associated with donor, but not recipient, JC

95 Compared with no viruria (n=515), sustained viruria was associated with more putative rejection epis

96 table renal transplant recipients with JCPyV viruria was attempted.

97 in biopsy specimens even for patients whose viruria was cleared.

98 a made concurrent JC viruria less likely: JC viruria was detected in 22% of non-BK viruric recipients

99 JCV viruria was far more common (37%) than BKV viruria (5%)

100 %) of 54 urines, 2-80 weeks after infection; viruria was less frequent after 6 months.

101 Maternal CMV viruria was not associated with mean CD4 cell counts or

102 In summary, SV40 viruria was not detected among homosexual men who shed h

103 BK viruria was observed in 15.4% (6/39) of living donors an

104 BKV viruria was strongly associated with BKV viremia (93%),

105 JCV viruria, was more often asymptomatic (P=0.002) and affec

106 re Haufen-negative, however, high viremia or viruria were detected in 8% and 41% of control samples,

107 Viral loads in patients with asymptomatic viruria were generally lower but in some cases overlappe

108 Women with detectable peripartum CMV viruria were more likely to have infants with cCMV than

109 Both baseline PCR viremia and PCR viruria were significantly associated with future cytome

110 JCV and BKV virurias were 46.7% and 0%, respectively.

111 of clinical presentations from asymptomatic viruria with pyuria to ureteral ulceration with ureteral

112 episodes (52.1%) occurred concurrently with viruria, with a minority before (7.8%) or after (40.1%)